Active	Status	Sponsor type	Region	Phase	Filter
8 Active 1 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Demko, Zachary
SPARO, NCT03984747: Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection	Completed	N/A	110	US		Natera, Inc.	Transplant Rejection, Allograft Rejection, Complications	08/24	08/24
Faravardeh, Arman
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients	Terminated	3	194	Europe, Canada, US, RoW	Clazakizumab, Physiologic saline solution	CSL Behring, ICON Clinical Research	Antibody-mediated Rejection	04/24	04/24
ProActive, NCT04091984: The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry	Active, not recruiting	N/A	5000	US	Prospera	Natera, Inc., University of Maryland	Kidney Transplant Rejection	10/26	10/27
SPARO, NCT03984747: Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection	Completed	N/A	110	US		Natera, Inc.	Transplant Rejection, Allograft Rejection, Complications	08/24	08/24
Gripp, Eva
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients	Terminated	3	194	Europe, Canada, US, RoW	Clazakizumab, Physiologic saline solution	CSL Behring, ICON Clinical Research	Antibody-mediated Rejection	04/24	04/24
SPARO, NCT03984747: Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection	Completed	N/A	110	US		Natera, Inc.	Transplant Rejection, Allograft Rejection, Complications	08/24	08/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Demko, Zachary
SPARO, NCT03984747: Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection	Completed	N/A	110	US		Natera, Inc.	Transplant Rejection, Allograft Rejection, Complications	08/24	08/24
Faravardeh, Arman
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients	Terminated	3	194	Europe, Canada, US, RoW	Clazakizumab, Physiologic saline solution	CSL Behring, ICON Clinical Research	Antibody-mediated Rejection	04/24	04/24
ProActive, NCT04091984: The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry	Active, not recruiting	N/A	5000	US	Prospera	Natera, Inc., University of Maryland	Kidney Transplant Rejection	10/26	10/27
SPARO, NCT03984747: Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection	Completed	N/A	110	US		Natera, Inc.	Transplant Rejection, Allograft Rejection, Complications	08/24	08/24
Gripp, Eva
IMAGINE, NCT03744910 / 2018-003682-34: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients	Terminated	3	194	Europe, Canada, US, RoW	Clazakizumab, Physiologic saline solution	CSL Behring, ICON Clinical Research	Antibody-mediated Rejection	04/24	04/24
SPARO, NCT03984747: Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection	Completed	N/A	110	US		Natera, Inc.	Transplant Rejection, Allograft Rejection, Complications	08/24	08/24